XPO1 E571K

Other names: XPO1, Exportin 1, CRM1, Chromosome Region Maintenance 1 Protein Homolog, Exportin 1 (CRM1 Homolog, Yeast), Exportin-1, CRM-1, Exportin-1 (Required For Chromosome Region Maintenance), Chromosome Region Maintenance 1 Homolog (Yeast), Chromosome Region Maintenance 1 Homolog
Entrez ID:
Related biomarkers:
Allogeneic Stem Cell Transplantation Improves Survival in North American Adult T-Cell Leukemia & Lymphoma NA-ATLL with CNS Involvement with Minimal Graft Versus Host Disease GVHD (TCT-ASTCT-CIBMTR 2022)
Although CNS involvement in NA-ATLL portends a poor prognosis, a sizable number of patients can be offered allogeneic grafting as a safe and potentially curative treatment.
Clinical • IO biomarker
XPO1 (Exportin 1)
XPO1 E571K • XPO1 mutation
Simultaneous Disruption of XPO1 and A20 in Murine B Cells Influences Both B and T Cell Repertoire (ASH 2021)
Significance : We report that simultaneous disruption of essential regulators XPO1 and A20 in murine B cells encourages development of irregular B and T cell populations, and can stimulate a progressive CLL-like or T cell leukemia-like expansion. Continued investigation with these models can further our understanding of the relationship between overall immune function and these critical regulatory molecules, and can provide considerable insight to identifying pathways for selective targeting as a personalized therapy in several high-risk cancer types.
Preclinical • IO biomarker
CD19 (CD19 Molecule) • TNFAIP3 (TNF Alpha Induced Protein 3) • XPO1 (Exportin 1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
XPO1 E571K • TNFAIP3 mutation • CD19 expression • XPO1 mutation
[VIRTUAL] Primary Mediastinal Large B-Cell Lymphoma in a 15-Year-Old Adolescent Male: A Rare Case Report With Complex Genomic Findings Refractory to Standard Therapy and Review of the Literature (CAP 2021)
Also, some of these genetic aberrations like MAP2K1 and PAX5 were associated with worse prognosis. Our patient had little response despite standard therapy, hence we conclude that a poor prognosis could be associated with these genetic alterations.
Clinical • Review • PD(L)-1 Biomarker • IO biomarker
PD-L1 (Programmed death ligand 1) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PAX5 (Paired Box 5) • TNFAIP3 (TNF Alpha Induced Protein 3) • SOCS1 (Suppressor Of Cytokine Signaling 1) • CD200 (CD200 Molecule) • CD58 (CD58 Molecule) • NFKBIA (NFKB Inhibitor Alpha 2) • FCER2 (Fc Fragment Of IgE Receptor II)
CD20 positive • XPO1 E571K
[VIRTUAL] Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 and SF3B1 mutant hematologic malignancies (AACR 2021)
We therefore hypothesized that combining selinexor and venetoclax would have potential synergy and could be used to target hematologic malignancies bearing XPO1 and SF3B1 mutations.We first determined whether XPO1 and SF3B1 mutant cell lines showed differential response to either selinexor or venetoclax monotherapy. This combination is highly promising as an all oral regimen for hematologic malignancies bearing these mutations. Further, preclinical testing in in vivo using XPO1 and SF3B1 mutant and wildtype mice is ongoing.
IO biomarker
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • SF3B1 (Splicing Factor 3b Subunit 1) • XPO1 (Exportin 1) • RELA (RELA Proto-Oncogene)
SF3B1 mutation • SF3B1 K666N • XPO1 E571K • XPO1 mutation
Venclexta (venetoclax) • Xpovio (selinexor)